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Analysis o f eicosanoids released from activated macrophages (94 pp.)
Director: George L. Card

Macrophages are a major source o f the eicosanoid derivatives o f arachidonlc acid,
which mediate a number o f reactions that have important biological functions.

In

this study, w e developed a C18 minicolumn procedure for rapidly separating
eicosanoid mixtures into prostaglandin, leukotriene, and arachidonic acid fractions.
The procedure was then used to quantify eicosanoids released from macrophages (both
human THP-1 cells and mouse peritoneal exudate cells) activated with different
bacterial amphiphiles (lipopolysaccharide (LPS), lipoteichoic acid (LTA), and
monophosphoryl lipid A), ceramide, and phorbol myristate acetate (PMA).
Arachidonic acid was the main product in eicosanoid mixtures released from both cell
lines. The prostaglandin pathway was activated in mouse PEC, but not in human
THP-1 cells. There were marked differences in the relatgive potency o f different
amphiphile preparations for the activation o f both cell types. Pretreatment o f THP-1
cells with 7-interferon was not required for the activation o f arachidonic acid
metabolism in the human THP-1 cell line. Treatment with R595 LPS desensitized
mouse PEC to subsequent challenge with R595 LPS, but not with either C2-ceramide
or PM A. HPLC analysis confirmed that arachidonic acid was the main product
released from activated THP-1 cells and suggested that the eicosanoid mixtures
released from acitivated cells contained products other than prostaglandins,
leukotrienes, and arachidonic acid.
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Chapter

I

Introduction
Activated macrophages play a critical role in host
defense against tumors and microbes, in the development of
an inflammatory response, in homeostasis and in diseases
such as atherogenesis, and carcinogenesis. Macrophages
possess numerous physiologic properties that may be
modulated during activation. These include alterations in
intracellular constituents, plasma membrane components, and
secretion of both protein and lipid mediators

(1).

As shown in Fig 1, a variety of metabolic activities
have been described in activated macrophages. The metabolic
activities which are commonly used to measure macrophage
activation include the respiratory burst, secretion of
proteins and glycoprotein mediators, release of tumor
necrosis factor(TNF) and other cytokines, display of altered
surface properties,and the release of arachidonic acid
metabolites (eicosanoids)(4).
Arachidonic acid is an essential fatty acid which is
incorporated into membrane phospholipids. The products of
arachidonic acid metabolism (eicosanoids) mediate a number
of reactions that have various important biological effects.
It has also been suggested that the release of other
mediators

(e.g. cytokines) may be dependent on the

activation of arachidonic acid metabolism. Macrophages are a
major source of the eicosanoids and, by consideration of
their importance in host defense, it is clear that their
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release constitutes an important aspect of macrophage
function.
The activity of macrophages is regulated by
extracellular signals which can either enhance or diminish
the ability of macrophages to carry out a certain function.
Bacterial amphiphiles, including lipopolysaccharides,
lipoteichoic acids, monophosphoryl lipid A, etc., are
substances which can enhance the immune response by causing
sensitive cells, such as macrophages, neutrophils and
lymphocytes, to release a variety of mediators (4). These
mediators act as messengers which have many significant
biological functions, including inflammation(interleukins,
eicosanoids), tumor destruction (tumor necrosis factor),
lymphocyte activation (interleukins). This study was focused
on, the release of eicosanoids (arachidonic acid metabolites)
by the macrophages (murine and human THP-1) activated with
different bacterial amphiphiles.

ARACHIDONIC ACID
Eicosanoids are derivatives of arachidonic acid, a C20
polyunsaturated fatty acid (5-cis-, 8-cis-, 11-cis-, 14-ciseicosatetraenoic acid)

(4)

(Fig. 2). After activation of

phospholipase A2, arachidonic acid is released from membrane
phospholipid, and is then converted to different eicosanoid
products. There are three major classes of eicosanoids which
are produced by three major eicosanoid biosynthetic
pathways: the cyclooxygenase pathway (prostaglandins), the
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5-09>, 8c(s-, ^^-cb~,^A'Ci$•&œ$atetraenoicadd
Fig. 2: Structura of a arachidonic acid
5 '-lipoxygenase pathways (leukotrienes), and the 12'- and
15'-lipoxygenase pathway (lipoxins).
The synthesis of the prostaglandin family begins with
the enzyme cyclooxygenase. Phospholipase A2, which liberates
arachidonic acid from the phospholipids in cell membranes,
is the rate-limiting step in eicosanoids synthesis (Fig.3,
4)

.

LEUKOTRIENES
The leukotrienes (LTs) are a family of biologically
active lipids derived from arachidonic acid by the action of
a 5'-lipoxygenase (26) , They are produced from
polymorphonuclear cells, neutrophils, eosinophils,
monocytes, lymphocytes, macrophages, and mast cells (16).
This family includes the dihydroxyeicosanoid LTB4, a potent
chemotactic agent, and the peptidolipid leukotrienes LTC4,
LTD4 and LTE4, which are responsible for the potent smooth
muscle contractile effect of slow-reacting substance of
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anaphylaxis (SRS-A)(26). Leukotrienes C4 and D4 have been
shown to be potent myotropic agents, while Leukotriene E4 is
somewhat less potent. These and other products of the
lipoxygenase-pathway have been implicated in the pathology
of asthma and other hypersensitivity reactions (6). In
addition, the eukotrienes have potent effects on white cell
function,

(including a variety of phagocytic cells, as well

as lymphocytes), bronchial tone, and several other
biological target systems (21).
Because of so many important biological functions and
profound biochemical effects, this family has been the
subject of intense interest and there has been considerable
recent interest in quantifying these compounds in biological
samples.

PROSTAGLANDINS
Prostaglandins are cyclopentanoic acids derived from
arachidonic acid which exert hormone-like effects in many
physiological processes. The primary prostaglandins are
divided into three types based on the functionality in the
cyclopentane ring - E type (p-hydroxy-ketones), F type (1,3diols), and A type (a,p-unsaturated ketones). The natural
prostaglandins are also grouped into the mono-, bis-, or
trisunsaturated classes, according to the number of carboncarbon double bonds in the parent E-type prostaglandin. All
of the prostaglandins have in common the prostanoic acid
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skeleton, and typical prostaglandins, like PGE2, have four
oxygen-functionalized carbon atoms.
The biosynthesis of prostaglandins is initiated by an
enzyme associated with the endoplasmic reticulum, called
prostaglandin endoperoxide synthase. The enzyme catalyzes
simultaneous oxidation and cyclization of arachidonic acid.
The enzyme has two distinct activities, cyclooxygenase and
peroxidase(Fig.5).
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Prostaglandins are released from many types of tissue
in response to injury such as anaphylactic shock, mechanical
trauma, and inflammation. Pharmacological properties of
prostaglandins include vasodilatation, increased vascular
permeability, and leukocytic emigration (10). Prostaglandins
cause either vasoconstriction or vasodilatation, depending
on the type of prostaglandin, the type of vascular bed and
the animal species. Prostaglandins of the A and E series, in
most vascular beds, induce vasodilatation of both arterioles
and venules. In man, intravenous prostaglandins cause
headache and also pain along the veins into which they are
infused. When administered intradermally or intramuscularly
in concentrations much higher than those expected to occur
in inflammation, PGEl causes a long-lasting overt pain. With
PGF2a, there is an initial brief effect followed by a
delayed gradual increase. In addition, PGEl can enhance the
granuloma formation by cotton pellets and increase collagen
synthesis in chick embryo tibiae. It is also the most
powerful pyretic agent known, when injected either into
cerebral ventricles or directly into the anterior
hypothalmus (10).
Prostaglandins are likely to be important in bone
metabolism because they are potent multifunctional
regulators of both formation and resorption. They are
produced in abundance by bone cells, and by the cells
adjacent to the bone in the marrow and the periosteal
tissues. Moreover, prostaglandins probably mediate the
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effects of mechanical forces on the skeleton. Thus they are
likely to play

a critical role in skeletal physiology and in

the pathologic

responses of bone. Recent studies have

confirmed that

prostaglandins, particularly PGE2, are potent

stimulators of

resorption that act by increasing both the

replication and differentiation of osteoclast precursors.
Prostaglandins have biphasic effects on bone formation. An
inhibitory effect on collagen synthesis can be demonstrated
in cell and organ culture and appears to be transcriptional,
acting through a PGF receptor that activates protein kinase
C (25). Several recent studies have shown that the lung is
one of the major sites of prostaglandin synthesis and
inactivation. A variety of physiological and pathological
stimuli including hypoxia, anaphylaxis and hyperinflation
cause the release of prostaglandins from lung. Thus, it has
been suggested that there is a relationship between the
ability of the lung to handle prostaglandin synthesis,
release and metabolism, and pulmonic diseases. In contrast
to the peptido-leukotrienes, inhaled prostaglandin E2
attenuates smooth muscle constriction in airway passages
(23) .
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BACTERIAL AMPHIPHILES
The bacterial amphiphiles which will be used in this
study include: lipopolysaccharide ( R-form LPS and S-form
LPS), monophosphoryl lipid A (MLA) and lipoteichoic acids
(LTA) from different gram-positive bacteria.

LIPOPOLYSACCHARIDES
Lipopolysaccharide (LPS) is the endotoxin which is
localized on the surface of bacterial cells, and, together
with phospholipids and proteins, forms the outer membrane of
Gram-negative bacteria (5). It can produce adverse reactions
including circulatory and metabolic failures and often
lethal shock in animals. These effects have been attributed
largely to the release of several chemical mediators such as
interleukins, TNF, and eicosanoids from macrophages. It is
well known that LPS is able to activate the complement
cascade and prime polymorphonuclear leukocytes or monocytesmacrophages to release these various mediators. The in vitro
culture of polymorphonuclear leukocytes or peritoneal
macrophages (PM) with LPS promotes an enhanced respiratory
burst and release of eicosanoids, events considered
important in the defense against bacterial infection as well
as in the progress of tissue damage (31) . The influence of
endotoxin on the biosynthetic processes of eicosanoids
remains unclear (8).
LPS is composed of three distinct structural parts:
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0-antigenic repeating polysaccharide, core-oligosaccharide.
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Fig. 6: Structure of lipopolysaccharide
and a hydrophobic component designated lipid A (29)

{Fig.

6) . Thereis considerable variation in the amounts of
polysaccharide in LPS so that some LPS consists
predominantly of lipid A and is called R-form LPS, whereas
others have abundant polysaccharide (the 0-side chain) and
is called S-form LPS. Although the lipid A part of LPS is
responsible for the endotoxic activities, the polysaccharide
moiety influences the elimination kinetics, mediates
specific LPS binding with macrophages and lymphocytes, and
is essential for activation of the alternate pathway of the
complement system (8). Since R-form and S-form LPS differ in
their relative contents of polysaccharide, it is possible
that they have differential effects on the release of
chemical mediators and subsequent pathophysiological
consequences.

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

13

MONOPHOSPHORYL LIPID A
Monophosphoryl lipid A (MLA) is an attenuated
derivative of LPS that lacks many of the endotoxic
properties of the parent molecule and yet retains potent
adjuvant and immunostimulating activities (Fig. 7) . MLA,
marketed as MPL immunostimulant, has been tested in several
clinical trials involving a variety of indications,
formulations, and routes of administration. Many
studies have shown that MLA is safe in humans at doses that
are active with respect to a number of immunological
markers, including induction of cytokines, activation of
cytotoxic T cells, and protection against a subsequent
endotoxin challenge (22). Other evidence has shown some
relationship between MLA and several mediators: MLA induced
rapid accumulation of interferon-gamma (IFN-y) in mice.

HO

Pig. 7: Structure of
monopho sphory1
lipid A
(MLA)

HO
NH
HO

HO
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Tumor necrosis factor-alpha (TNF-a) appeared to be a
cofactor for IFN-y induction by MLA. With low dose of MLA (<
5 micrograms), IFN-y induction was dependent upon exogenous
TNF-a administered either in advance of or with MLA (13).
The monophosphoryl lipid A homologs derived from
Salmonella minnesota strain R595 have been characterized by
the combination of FAB-MS (Fast atom bombardment and mass
spectrometry) and 2D nuclear magnetic resonance spectroscopy
which included a detailed evaluation of the hepta-, hexa-,
and pentaacyl MLA (5). This study was interested in
determining the effects of this partial structure of the
lipid A moiety of gram-negative lipopolysaccharide,
monophosphoryl lipid A, on eicosanoid metabolism in
macrophages.

LIPOTEICHOIC ACID
Lipoteichoic acid (LTA) is a different type of
amphiphile which is produced by Gram-positive bacteria (11)
(Fig. 8) . Most LTAs which have been characterized consist of
a 1,3, linked polyglycerophosphate moiety in a
phosphodiester linkage to a membrane hydrophobic
glyceroglycolipid which is anchored at the outer surface of
the cytoplasmic membrane, with the glycerophosphate chain
extending into the environment (4). This glyceroglycolipid
anchor is usually composed of a disaccharide unit linked to
a diacylglycerol. The length of the polyglycerophosphate
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Chain varies from 16 to 40 glycerophosphate units, depending
on the bacterial species (11,33).

'1

HC—0—00—A

Fig. 8: structure of lipoteichoic acid (Staphylococcus aureus)

The number of group substitutions in the glycerol residues
also varies among bacterial species. Bacterial LTAs can be
divided.into four groups based on the chain substitution:
group A lacks substituents; group B carries only D-alanine
substituents; group C carries only glycosyl substituents;
and group D carries both of these substituents (4).
It has been well known that the inflammatory components
implicated in gram-positive bacteremia are cell wall
components, toxins, and enzymes. The role of LTA in grampositive bacterium inflammation has not been well
documented. Some recent research reported that although it
was relatively non-toxic, lipoteichoic acids could activate
arachidonic acid metabolism and eicosanoid release from
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macrophages (17). There is some evidence to show that there
are humoral and cellular factors that recognized both LPS
and LTA, and LTA had some immunological and biological
properties in common with LPS (2,14).
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OBJECTIVES
The major objective of this study was to compare the
relative amounts of leukotrienes, prostaglandins, and
arachidonic acid released from macrophages activated with
different bacterial amphiphiles, including ipopolysaccharide
(S-form LPS and R-form LPS) and monophosphoryl lipid A (MLA)
from Gram-negative bacteria, lipoteichoic acid (LTA) from
Gram-positive bacteria, and phorbol myristic acetate (PMA).

SPECIFIC AIMS
(1) .

An analytical strategy was developed for the rapid
extraction, separation, and quantification of the
relative amount of leukotriene, prostaglandin and
arachidonic acid released from activated macrophages.
Procedures currently available for eicosanoid
analysis are expensive (e.g. EIA, RIA) and/or very time
consuming (e.g. HPLC). Although these have been useful
for some clinical studies and other experiments
involving a limited number of samples, they are not
suitable for the analysis of a large number of samples.

(2). This procedure was used for an analysis of the relative
amount of prostaglandin, leukotriene, and arachidonic
acid released from macrophages treated with different
bacterial amphiphiles.
The analytical strategy developed in Specific
Aim#l would allow the screening of a large number of
samples. The working assumption is that substances
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which activate cells to produce markedly different
mixtures of prostaglandins and leukotrienes will have
different activities in whole animals.
(3) .

Selected amphiphiles (based on the results
obtained in Specific Aim #2) were used to study the
relative kinetics of prostaglandin and leukotriene
release from activated macrophages.
Some studies suggest that the accumulation of one
eicosanoid (e.g. PG-E2) may cause a down-régulâtion of
the synthesis of other eicosanoids.

(4).

Samples which showed significant differences of
the relative amounts of leukotriene and prostaglandin
were selected for complete analysis by HPLC and EIA
assay. These procedures provide the quantitative
analysis of each of the major prostaglandins and
leukotrienes as well as arachidonic acid and other
derivatives. Likewise, samples from the kinetic
experiments which showed significant changes of
eicosanoid families over time were analyzed with HPLC
and EIA assay.

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

19

Chapter II
Materials and Methods

Materials
Octadecyl (C18) minicoluitms were purchased from
Amersham International (Amersham Place, Buckinghamshire,
England). Labelled fatty acid and eicosanoids were purchased
from American Radiolabeled Chemicals Inc (St.Louis, MO).
Unlabeled lipids, Cellgro RPMI 1640 medium, and fetal bovine
serum (FES) were obtained from Sigma Chemicals (St.Louis,
M O ) . Six to ten week-old ICR mice were obtained from Jackson
laboratory. THP-1 cells, LPS preparations, and vitamin D3
(a-1, 25 dihydro-xyvitamin D) were provided by Ribi
ImmunoChem Research Institute (Hamilton,MT). LTA
preparations were from Sigma Chemicals (St. Louis, MO),
and Ecolume fluor was obtained from ICN Biochemicals
(Irvine, CA) . Prostaglandin E2 and Leukotriene C4 Enzyme
Immunoassay Kits were obtained from Cayman Chemical Company
(Ann Arbor, MI).

Fractionation of eicosanoids on C18 minicolumns
Initial studies were focused on the development of onestep column-centrifugation procedures for the rapid
separation of leukotrienes, prostaglandins and arachidonic
acid. The reverse-phase C18 bonded silica gel has been
proven to be very effective for extraction of prostaglandins
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and leukotrienes from biological fluids (27), Known mixtures
of prostaglandin E2 (PGE2), leukotriene D4 (LTD4) and
arachidonic acid (AA) containing tritium-labelled lipid were
used to evaluate the separation procedures. Three mixtures
of known lipids were used; each contained a mixture of
unlabelled PGE2 (280 pmole), LTD4 (200 pmole), and
arachidonic acid (1000 pmole) plus one labelled lipid.
Mixture 1 contained the unlabelled lipid mixture plus ^HPGEl (0.1 (iCi), mixture 2 contained the unlabelled lipid
mixture plus ^H-LTD4 (0.01 nCi)/ and mixture 3 contained the
unlabelled lipid mixture plus ^H-arachidonic acid (0.15
|iCi) .
Solvent systems and elution schemes evaluated in this
study were selected from solvent systems which have been
used in HPLC and TLC (thin layer chromatography) procedures
for separation of these lipids (28,30). The following
solvents were selected for the final elution scheme: solvent
A (A) , acetonitrile-methanol-ddH20-acetic acid-EDTA
(1280:800:1916:4:2 grams); solvent B (B), solvent A-methanol
(50:50); solvent C (C), solvent A-ddHaO (75:25); solvent D
(D) , solvent A-methanol (75:25); and methanol. Samples were
applied to the C18 minicolumns in water. Prostaglandins were
eluted by successively pushing 1 ml each of solvents C, A,
and D through the minicolumn with a 1 ml syringe.
Leukotrienes were then eluted with solvent B, and finally
arachidonic acid was eluted with methanol. Labelled lipid in
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each fraction was counted in a Beckman LS7500 scintillation
counter.

Macrophage Cultures
Two types of macrophage cultures were used in this
study: mouse peritoneal exudate cells (mouse PEC) and human
THP-1 monocytic cells. These two cell lines have been well
characterized as excellent models for the study of murine
and human macrophages, respectively.

Mouse Peritoneal Exudate Cells
Mice were killed with CO2 and PECs were recovered by
injecting 10 ml of RPMI medium containing 20 )ig/ml of
gentamicin into the peritoneal cavity. Peritoneal fluids
were removed, transferred to a centrifuge tube, and
centrifuged at 1000 rpm for 10 minutes. The cells were then
resuspended in 10 ml of RPMI medium, counted using a
hemacytometer, and the cell density was adjusted to 2 - 2.5
X

10® cells/ml. The cell suspension was added (1.0 ml/well)

to a 24 well flat-bottom plate. Cells were incubated at 37°C
in a chamber with 5% CO2 for 2 hours to allow macrophages to
adhere. Non-adherent cells were then removed and fresh
medium was added.

Human THP-1 Cells
Human THP-1 cells were grown in RPMI medium containing

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

22

10% FBS serum in 75 cm^ sterile tissue culture flasks at
37°C in 5% CO2 . The cell density was adjusted to 1.5 - 2.5 x
10^ cells/ml.

Bacterial Amphiphiles
Bacterial amphiphiles which were used in this study
included 1ipopolysaccharide (LPS) and lipoteichoic acid
(LTA) preparations which have been shown to activate total
arachidonic acid metabolism (4). LPS preparations included
smooth LPS from Salmonella abortus (S-LPS), rough LPS from
Salmonella minnesota R595 (R-LPS), diphosphoryl lipid A
(DPL) and monophosphoryl lipid A (MLA) obtained from R-595
LPS, and deacylated LPS preparations. LTA preparations
included LTA from Bacillus subtilis, Staphylococcus aureus,
Streptococcus pyogenes, and S. faecalis.

Labeling Procedure
[^H] arachidonic acid was used to metabolically label
the eicosanoids.

Adherent mouose peritoneal exudate cells on

the 24-well plate were washed with fresh medium, and then 1
ml of medium containing [^H]-arachidonic acid (0.5 jiCi/well)
was added to each well. Cells were then incubated overnight
at 37°C in 5% CO2 .
Human THP-1
pM/ml) overnight

cells were pretreated withvitamin D3 (1
in a 75 cm^ sterile tissue culture flask at

37°c in 5% CO^. After overnight pretreatment, cells were
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harvested, counted, and transferred to a centrifuge tube,
centrifuged at 1000 rpm for 10 minutes. Then the cells were
resuspended in 24 ml of RPMI medium with 10% FBS serum
containing

-arachidonic acid (0.5 |iCi/ml). The cell

suspension was then added (1.0 ml/well) to a 24 well flatbottom plate, and incubated overnight at 37°c in 5% CO2. At
the end of the overnight incubation, the unincorporated
label was removed and the cells were washed three times with
fresh medium.

Macrophage Challenge
Cells were challenged in medium with serum with an
amphiphiles, or ceramide, or phorbol myristate acetate
(PMA) . Cells were incubated at 37°C with 5% CO2 for
different challenging time period, and/or with different
concentrations of the bacterial amphiphiles, as indicated.
At the end of the incubation period the medium from each
well was collected and centrifuged in an Eppendorf 5414
table top centrifuge to remove any cells. Lipids released
from cells labeled with [^H]-arachidonic acid was determined
in 100 (il from each sample collected in scintillation vials
with 4 mis of Ecolume fluor. The remaining 900 |il from each
sample was analyzed with the C18 minicolumn separation
procedure for analysis of the relative amount of
prostaglandins, leukotrienes and arachidonic acid as
described above.
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Samples which showed significant differences in the
relative amounts of leukotrienes and prostaglandins were
selected for complete analysis by HPLC.

HPLC Analysis
The high-performance liquid chromatograph was performed
with a 4.6 X 250 mm Silica C18 column, which was attached to
a PERKIN-ELMER Series 410 LC Pump, a FLO-ONE\Beta Series A100 radioactivity detector, and a PERKIN-ELMER LC-90 UV
Spectrophotometric detector. The solvent system was a gradi
ent of solvnet A (acetonitrile:methanol:ddH20:acetic acid:EDTA = 1280 ;800 ;1916: 4 :2 gram) and methanol eluted at
the flow rate of 1 ml/min in the following order: 0 min,
100% A; 30 min, 100% A; 31 min, 100% methanol; 51 min, 100%
methanol; 52 min, 100% A; 67 min, 100% A. Tritium-labelled
PGEl, LTD4, and arachidonic acid were selected as standards
which were the representative of different eicosanoid fami
lies for the radioactivity detector.
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Chapter III
RESULTS

Binding Affinity of Different Eicosanoids on CIS Minicolumns
Initial studies were focused on an analysis of the
binding affinity of eicosanoids on C18 minicloumns. Samples
consisted of 280 pmole of unlabelled PGE2, 1100 pmole of
unlabelled arachidonic acid, and 200 pmole of unlabelled
leukotriene D4 plus either 0.1 p,Ci of ^H-PGEl or 0.01 |iCi of
^H-LTD4 in 1 ml of RPMI with 10% FBS culture medium. RPMI
medium with 10% FBS serum, which was used for culturing both
mouse and human THP-1 macrophages, was added to make the
final vaule of each sample to be 1 m l . A 50 p.1 aliquot from
each sample was removed to determine total CPM loaded on the
columns. The remaining portion of each sample was loaded
onto each of two Cl8 minicolumns. After each sample passed
through the column, a 50 [xl aliquot of the eluate was
counted to determine the amount of labelled eicosanoid which
was not bound on the column. Over 96% of ^H-PGEl and 88% of
^H-LTD4 were bound to the Cl8 minicolumns. The amount bound
was not significantly increased by passing the effluent
through the columns a second time.

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

26

Binding Affinity of Different Eicosanoids on Silicic Acid
Columns
The binding of PGEl and LTD4 to silicic acid was
measured in different solvents in order to select the most
appropriate solvent for loading and eluting samples. The
following solvents were selected for this study; 99%
ethanol, e t h a n o l (4:1), ethanol :H2 O (2:1), ethanol:H20
(1:4), hexane, toluene, and methanol. Samples, 100 |il each,
consisted of mixed unlabelled eicosanoids as described
above, were labelled with either 0.1 p.Ci [^H] -PGEl or 0.01
|iCi [^H]-LTD4. 400 |j,l of each solvent listed above was added
to make the final vaule of each sample to be 0.5 ml. A 10 pi
aliquot from each sample was removed to determine total CPM
loaded. Silicic acid was loaded into 1.5 ml centrifuge
tubes, 40 mg each tube. Samples were then loaded into the
tubes and mixed with silicic acid. After 15 mintues, all
tubes were centrifuged at 14,000 rpm for 30 seconds, and a
10 pi aliquot of the supernatant of each sample was removed
to determine the amount of labelled eicosanoids which did
not bind to the silicic acid in the centrifuge tubes. Our
results indicated that among the different solvents listed
above, eicosanoids had high binding affinity with silicic
acid in either hexane or toluene. Over 98.7% of ^H-PGEl and
98.3% of ^H-LTD4 bound with silicic acid in hexane, and over
98.6% of ^H-PGEl and 98.1% of ^H-LTD4 bound with silicic
acid in toluene. Based on these results, toluene was
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selected as the first solvent in the elution system.

Separation of Leukotrienes, Prostaglandins, and Arachidonic
Acid on CIS Minicolumns
Three samples which consisted of the unlabelled
eicosanoid mixture described above were labelled with [^H]PGE2,

[^H]-LTD4, or

-AA. A 50 f^l aliquot was taken from

each sample and counted to determine total CPM loaded on the
columns. The remaining portion of each sample was loaded
onto CIS minicolumns, and eluted successively with solvents
C, A, and D (fraction #1), solvent B (fraction #2), and
finally methanol (fraction #3). The recovery for [^H]-PGE2,
[^H]-LTD4, and [^H]-AA was 89%, 54.34% and 96%, respectively
(Fig. 9).
A sample containing a mixture of labelled PGE2 (36.6%
of total), LTD4 (15.3% of total), and arachidonic acid
(48.1% of total) was loaded onto the CIS minicolumn. As
shown in (Fig. 10), the amount recovered in each fraction
was almost identical to the expected value.
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Fig. 9: Separation of standard mixture of prostaglandins,
leukotrienes, and arachidonic acid on CIS minicolumn.
The standard mixture of unlabeled eicosanoids consisted of
280 pmole of PGE2, 1100 pmole of arachidonic acid, and 200
pmole of leukotriene D 4 . Mixture #1, 2, and 3 consisted of
the standard mixture plus labeled ^H-PGEl (0.1 jiCi/sample)
(solid bar), ^H-LTD4 (0.01 jiCi/sample)(spotted bar), and
AA (0.12 |iCi/sample) (hatched bar), respectively. The lipid
was applied to a C18 minicolumn in RPMI medium.
Fraction 1
was eluted with solvent C, A and D, successively, fraction 2
with solvent B, and fraction 3 with methanol.
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Fig. 10: Fractionation of an eicosanoid mixture on Cl8
minicolumns.
A known mixture consisting of 0.1 fxCi ^H-PGEl, 0.01 p,Ci
LTD4/ and 0.12 jiCi ^H-AA was fractionated on C18 minicolumn
as described in the legend of Fig. 9. The amount of label
recovered in each fraction (solid bar) is compared to the
actual amount of each labeled lipid added to the mixture
(hatched bar).
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Separation of Leukotrienes, Prostaglandins, and Arachidonic
Acid on Silicic Acid Columns
Three samples which consisted of the unlabelled
eicosanoid mixture as described above were labelled with 0.1
^iCi [^H]-PGE1, 0.01 nci [^H]-LTD4, or 0.12 nCi [^H]-AA. A 10
|i,l aliquot from each sample was removed to determine total
CPM loaded on the column. Silicic acid was loaded onto
centrifuge columns, 60 mg each column. Samples were then
loaded onto each one of three centrifuge columns, and
sequentially eluted twice with each of the following
solvents: toluene, solvent A1 (toluene;ethyl
acetate :methanol=60:40 :0), solvent A2 (toluene: ethyl
acetate : methanol=60:40:2), solvent A3 (toluene :ethyl
acetate: methanol= 60:40:20), solvent B1 (acetonitrile:
methanol: ddH20:acetic acid :EDTA=1280:800:1916: 4 :2 grams),
solvent B2 (solvent Bl:methanol= 50:50), and methanol. As
shown in Fig 11, the silicic acid column procedure could
separate LTD4 from both PGEl and arachidonic acid, but it
was not effective for separation of prostaglandins and
arachidonic acid. In order to confirm this separation
result, fraction #3, 4, and 5, which had the highest CPM
counts from the ^H-PGEl-silicic acid column, were mixed
together as sample A. And fraction #9 and 10, which had the
highest CPM counts from ^H-LTD4-silicic acid column, were
also mixed together as sample B. Sample A and B were then
dried, resuspended in 100 jil of 99% ethanol each, loaded
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onto each of two new silicic acid columns, respectively, and
eluted as described above. The results, as shown in Fig 12,
confirmed that ^H-PGEl were eluted with toluene, solvent Al,
A2 and A3, and ^H-LTD4 were eluted with solvent B1 and B2 ,
Based on these findings, we defined the toluene - solvent Al
” A2 - A3 as the prostaglandin fraction, and Solvent B1 - B2
- methanol as the leukotriene fraction.
In order to compare the separation effectiveness of the
silicic acid column procedure and the C18 minicolumn
procedure, three samples containing a labelled mixture of
^H-PGEl only, ^H-LTD4/^H-PGE1 = 38/62, or ^H-LTD4 only, were
loaded onto each of three silicic acid columns and eluted as
described above. The amount of label recovered in each
fraction was closer to the applied value for the C18
minicolumns {Fig. 10) than for the silicic acid columns
(Fig. 13) .
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Fig. 11: Separation of the standard mixture of
prostaglandins, leukotrienes, and arachidonic acid on
silicic acid columns.
Mixture #1 (solid bar), #2 (hatched bar), and #3 (open bar)
were prepared as described in Fig. 9. The lipid was applied
to the silicic acid columns in RPMI medium. Fraction: T
(toluene); Al(toluene :ethyl acetate:methanol=60:40 :0); A2
(toluene:ethyl acetate:methanol=60:40:2) ; A 3 (toluene :ethyl
acetate:methanol=60:40:20); B 1 (acetonitrile:methanol:ddHzO
:acetic acid:EDTA=1280:800:1916:4:2 grams); B 2 : (B1:methanol=
50:50); M:methanol.
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Fig. 12: Confirmation of the separation efficiency of
prostaglandins and leukotrienes on silicic acid column.
Fraction #3, 4, and 5 from the ^H-PGEl-silicic acid column
as shown in Fig. 11 were mixed together as sample
PGEl", and fraction #9 and 10 from the ^H-LTD4-silicic acid
column in Fig. 11 were mixed as sample "B:^H-LTD4". Samples
A and B were then dried, resuspended in 100 |il of 99%
ethanol, loaded onto two new silicic acid columns, and
eluted as described in the legend of Fig. 11.
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Fig. 13: Fractionation of an eicosanoid mixture on silicic
acid columns.
Three samples# each cotaining the standard unlabeled mixture
as described in Fig. 9 plus H-PGEl only (Sample #1)#
LTD4/^H-PGEl=38/62 (Sample #2), and ^H-LTD4 only (Sample
#3), were fractionated on three silicic acid columns as
described in the legend of Fig. 11. The amount of label
recovered in each fraction (solid bar) is compared to the
actual amount of each labeled lipid added to the mixture
(hatched bar).
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The relative Amount of Label in the Different Eicosanoid
Fractions Released from LPS Activated THP-1 Cells Was
Similar Throughout the Activation Period
THP-1 cells (5.25 x 10^ cells/ml x 20 ml) were
pretreated with vitamin D3 (1 [iM/ml) and metabolically
labelled with [^H] arachidonic acid (0.5 |iCi/ml) overnight.
The cells were then challenged with smooth-LPS from S.
abortus or rough-LPS from S. minnesota (R595) at a
concentration of 1000 ng/ml. One ml samples were removed at
0, 15, 30, 60, 90, and 120 minutes after the addition of
LPS, and then centrifuged. A 100 pi aliquot of the
supernatant was removed from each sample and counted for
total label released {Fig. 14]. The remaining portion
of each sample was subsequently fractionated on C18minicolumns. The major eicosanoid recovered at each time
point was arachidonic acid. Only trace amounts of label were
recovered in the prostaglandin or leukotriene fractions in
the mixture released from S. abortus LPS treated cells.
{Fig. 15). Less than 5% of the total bound lipid was
recovered in the prostaglandin fraction of the lipid
released from the cells challenged with R595 LPS, and both
arachidonic acid (40% to 60%) and leukotrienes (20% to 30%)
were recovered from C18 minicolumn separation (Fig. 16). In
addition, between 30% and 40% of the label released from the
cells did not bind to the Cl8-minicolumns when applied in
RPMI medium. These products were apparently quite polar.
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Pig. 14: Time course for label released from human THP-1.
cells challenged with S.abortus or S.minnesota (R595) LPS.
Human THP-1 cells (8.7 x 10^ cells/ml x 40 ml) were
pretreated with vitamin D3 (1 liM/ml) and metabolically
labelled with ^H-arachidonic acid (0.5 pCi/ml) overnight.
The cells were then challenged with either S.abortus LPS or
S.minnesota LPS at a concentration of 1000 ng/ml in RPMI
medium with 10% FBS. One ml samples were removed at 0, 15,
30, 60, 90, and 120 minutes after the addition of LPS, and
centrifuged. A 100 |al aliquot of each supernatant was
counted to determine total label released from the cells.
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Fig. 15: Time course for eicosanoid release from activated
human THP-1 cells challenged with S. abortus LPS.
THP-1 cells were pretreated and challenged as described in
the legend of Fig. 14. After the 100 ji.1 aliquot from each
sample was taken to be counted/ the remaining portion of
each sample was fractionated on CIS minicolumns as described
in the legend of Fig. 9. Unbound: ^H-labelled polar
products which did not bind to the CIS minicolumn;
PG:prostaglandin family; LT: leukotriene family; AA:
arachidonic acid family.
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Fig. 16: Time course for eicosanoid release from activated
human THP-1 cells challenged with S. minnesota LPS.
Human THP-1 cells were pretreated and challenged as
described in the legend of Fig. 14. After the 100 pi
aliquot was removed from each sample to be counted, the
remaining portion of each sample was fractionated on CIS
minicolumns as described in the legend of Fig. 9. Unbound:
^H-labelled polar products which did not bind to the C18
minicolumn;
PG: prostaglandin family; LT: leukotriene
family; AA: arachidonic acid family.
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THP-1 Macrophages Activated with LPS from S. minnesota
(R595) Released Both PGEz and LTC,
In order to quantify individual eicosanoids, EIA kits
were used to analyse the lipids released from human THP-1
cells activated with S. minnesota LPS.
THP-1 cells (7.4 x 10^ cells/ml x 20 ml) were
pretreated with vitamin D3 and metabolically labelled with
^H-arachidonic acid overnight as described above. S.
minnesota LPS was then used to challenge the cells at a
concentration course of 0, 0.1, 1, 10, 100, 1000 ng/ml
following the same experimental procedure as previous.

As

shown in Fig. 17, S. minnesota LPS activated arachidonic
acid metabolism in THP-1 cells. The Prostaglandin E2 and
Leukotriene C4 Enzyme Immunoassay kits were used to analyse
eicosanoids released from the cells. As shown in Fig. 18,
both prostaglandin E2 and leukotriene C4 were recovered, and
the results also showed that more leukotriene C4 was
released than the amount of prostaglandin E 2 .
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Fig. 17; CPM released from human THP-1 cells challenged at
various concentrations with S. minnesota LPS (R595).
Human THP-1 cells (6.9 x 10^ cells/ml x 20 ml) were
pretreated and labelled as described in the legend of Fig.
14. The cells were then challenged with S. minnesota LPS at
the concentration course of 0, 0.1, 1, 10, 100, 1000 ng/ml
in RPMI medium with 5% FBS for two hours. One ml samples
were then collected, centrifuged, and a 100 jil aliquot of
each supernatant was counted to determine total label
released from the cells.
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Fig. 18: Enzyme immunoassay analysis of eicosanoids
released from human THP-1 cells challenged with S.mlnnesota
LPS (R595) at various concentrations.
Human THP-1 cells were pretreated/ labelled, and challenged
as described in the legend of Fig. 17. A 50 p.1 aliquot of
each sample was analysed for prostaglandin E2 and for
leukotriene C4 with the specific EIA kits.
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The Kinetics of Activation of THP-1 Cells with Lipoteichoic
Acid were Similar to the Kinetics of Cells Activated with
LPS
THP-1 cells {7.5 x 10^ cells/ml x 20 ml) were
pretreated with vitamin D3 and metabolically labelled with
[^H]-arachidonic acid overnight as described above. The
cells were then challenged with LTA at a concentration of
1000 ng/ml following the same experimental procedure as
described above. S. faecalis LTA activated arachidonic acid
metabolism in human THP-1 cells {Fig. 19) . Samples were
collected at intervals and fractionated on CIS minicolumns.
Between 20% to 30% of the label released from the cells did
not bind to the column. The bound label was recovered
primarily in the arachidonic acid fraction (between 40%
and 60%) and the leukotriene fraction (between 20% to 25%)
(Fig. 20) .
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Fig. 19: Time course for label released from human THP-1
cells challenged with S, faecalis LTA.
Human THP-1 cells (7.5 x 10^ cells/ml x 20 ml) were
pretreated and labelled as described in the legend of Fig.
14. The cells were then challenged with S. faecalis LTA at
a concentration of 1000 ng/ml in RPMI medium with 10% FBS.
One ml samples were removed at 0, 15, 30, 60, 90, and 120
minutes after the addition of LTA, and centrifuged. A 100 pi
aliquot of each supernatant was counted to determine total
label released from the cells.
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Fig. 20: Time course for eicosanoid release from activated
human THP-1 cells challenged with S. faecalis LTA.
Human THP-1 cells were pretreated and challenged as
described in the legend of Fig. 19. After the 100 jal
aliquot was removed from each sample to be counted/ the
remaining portion of each sample was fractionated on CIS
minicolumns as described in the legend of Fig. 9. Unbound:
^H-labelled polar products which did not bind to the CIS
minicolumn;
PG: prostaglandin family; LT; leukotriene
family; AA: arachidonic acid family.
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The Relative Amount of Label Recovered in Different
Eicosanoid Fractions was Similar for THP-1 Cells Activated
with Different LTA preparations
THP-1 cells (3.4 x 10^ cells/ml x 15 ml) were
differentiated with vitamin D3 and labelled with ^Harachidonic acid as described above. The cells were then
challenged with LTA from S.pyogenes, B.subtilis, and
S.aureus in RPMI medium with 5% FBS for two hours. As shown
in Fig. 21, S.pyogenes, B.subtilis, and S.aureus LTA
activated arachidonic acid metabolism in THP-1 cells, and
S.aureus LTA appeared to have the most potent effect for
this activation. Samples from cells challenged with 1000
ng/ml of each amphiphile were analyzed on CIS minicolumns.
The relative amounts of prostaglandins, leukotrienes, and
arachidonic acid were similar for each of these LTA
preparations (Fig. 22) and the S .faecalis preparation {Fig.
20) . About 50% of the total label released from the cells
was recovered in arachidonic acid fraction, and about 10% of
the label was recovered in leukotriene fraction. Less than
2% of the label was found in prostaglandin fraction. Between
35% and 40% of the label did not bind to the CIS minicolumn.
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Fig. 21: Label released from human THP-1 cells challenged
at various concentrations with S.pyogenes, B.subtilis, and
S.aureus LTA.
Human THP-1 cells (3.3 x 10^ cells/ml x 15 ml) were
pretreated and labelled as described in the legend of Fig.
14. The cells were then challenged with S.pyogenes,
B.subtilis, and S.aureus LTA at the concentration course of
0, 0.1, 1, 10, 100, 1000 ng/ml in RPMI medium with 5% FBS
for two hours. All the samples were then collected,
centrifuged, and a 100 pi aliquot of each supernatant was
counted to determine total label released from the cells.
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Fig. 22: Eicosanoids released from activated human THP-1
cells challenged with 1000 ng of LTA from S.pyogenes,
B.subtilis, or S.aureus.
Human THP-1 cells were pretreated and challenged as
described in the legend of Fig. 21. After the 100 |xl
aliquot was removed from each sample to be counted, the
remaining portion of each sample was fractionated on CIS
minicolumns as described in the legend of Fig. 9. Unbound:
^H-labelled polar products which did not bind to the CIS
minicolumn;
PG: prostaglandin family; LT: leukotriene
family; AA: arachidonic acid family.
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Pretreatment of THP-1 Cells with Human Gamma Interferon did
not Alter the Pattern of Arachidonic Acid Metabolism

y-IFN pretreatment has a marked influence on the
response of some cells to LPS. Some macrophage cultures
require exposure to y-IFN in order to respond to LPS. To
determine the effect of y-IFN on arachidonic acid metabolism
in human THP-1 cell line, THP-1 cells {4.5 x 10^ cells x 30
ml) were pretreated with human y-IFN at 20 ng/ml during the
overnight labeling period. Cells without y-IFN pretreatment
were used as control. Cells were then challenged with R595
LPS in RPMI medium with 5% FBS for 2 hours. As shown in Fig.
23, arachidonic acid metabolism was activated in both y-IFN
pretreated and non-pretreated cells, and the activation was
almost identical in both cell preparations, indicating that
y-IFN was not required for activating arachidonic acid
metabolism in human THP-1 cell line.
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Fig. 23: Effect of human y-interferon on arachidonic acid
metabolism in human THP-1 cells.
Human THP-1 cells (4.5 x 10^ cells/ml x 30 ml) were
pretreated and labelled as described in the legend of Fig.
14. Half of the cells were pretreated with human yinterferon at 20 ng/ml overnight.
S.minnesota LPS was then
used to challenge both y-IFN pretreated (solid line) and
non-pretreated cells (broken line) in RPMI medium with 5%
FBS for two hours. One ml samples were then collected,
centrifuged, and a 100 (il aliquot of each supernatant was
counted to determine total label released from the cells.
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Mouse Peritoneal Macrophages (PEC) were More Sensitive to
PMA than Human THP-1 Macrophages
Some macrophage cultures {e.g. mouse peritoneal
macrophages) are very sensitive to the phorbol myristate
acetate (PMA). PMA is an analogue of diglyceride and
therefore does not require the amphiphile receptor(s) in the
membrane. To compare the effects of PMA, S. minnesota LPS,
and S. faecalis LTA on arachidonic acid metabolism in human
THP-1 monocytic cells and mouse PEC, THP-1 cells were
distributed into a 12-well flat-bottom plate at a
concentration of 4.8 x 10^ cells/well, and mouse PEC were at
a concentration of 1.9 x 10® cells/well. S. minnesota LPS,
S. faecalis LTA, and PMA were then used to challenge the
cells at a concentration of 1000 ng/ml in RPMI medium with
10% FBS. Three wells of the cells were used as controls for
unchallenged cells in each plate. After four hours
incubation at 37°C in a chamber with 5% CO 2 , one ml samples
were removed from each well, and then centrifuged. A 100 p.1
aliquot of the supernatant was removed from each sample and
counted for total label released. The remaining portion of
each sample was fractionated on C18 minicolumns.
S. minnesota LPS was the most potent activator (2000 ±
cpm/10^ cells), and PMA had the least effect (1000 ± cpm/10®
cells) in human THP-1 cells. In contrast to the THP-1 cells,
PMA had the strongest effect for the activation in mouse PEC
macrophages (Fig. 24) . The composition of the eicosanoid
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mixture released from PMA treated THP-1 cells was similar to
LPS and LTA treated cells (Fig. 25) . Mouse PEC cultures
released more label in the prostaglandin fraction than human
THP-1 cells (Fig. 26) .
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Fig. 24: Comparison of the effects of S. minnesota LPS,
S. faecalis LTA, and PMA on arachidonic acid metabolism in
human
THP-1 cells and mouse peritoneal macrophages (PEC).
THP-1 cells (9.6 X 10^ cells/ml x 40 ml) were pretreated and
labelled as described in the legend of Fig. 14. Mouse PEC
were collected (1.9 x 10^ cells/ml x 12 ml), washed with
RPMI medium without serum, and metabolically labelled with
^H-arachidonic acid (0.5 pCi/ml) overnight. Both of the
cell lines were then challenged with S. minnesota LPS, S.
faecalis LTA, or PMA at a concentration of 1000 ng/ml in
RPMI medium with 10% FBS for four hours. One ml samples
were then removed, centrifuged, and a 100 pi aliquot was
removed from each supernatant to be counted for total label
released from the cells.
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Fig. 25: Eicosanoids released from activated human THP-1
cells challenged with S. minnesota LPS, S. faecalis LTA, or
PMA.
THP-1 cells were pretreated and challenged as described in
the legend of Fig. 24. After the 100 pi aliquot was removed
from each sample to be counted, the remaining portion of
each sample was fractionated on C18 minicolumns as described
in the legend of Fig. 9. Unbound; ^H-labelled polar
products which did not bind to the C18 minicolumn;
PG:prostaglandin family; LT:leukotriene family; AA:
arachidonic acid family.
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Fig. 26: Eicosanoids released from activated mouse
peritoneal macrophages (PEC) challenged with S. minnesota
liPS, S. faecalis LTA, or PMA.
Mouse PEC were collected, washed, labelled, and challenged
as described in the legend of Fig. 24. After the 100 jil
aliquot was removed from each sample to be counted, the
remaining portion of each sample was fractionated on CIS
minicolumns as described in the legend of Fig. 9. Unbound:
^H-labelled polar products which did not bind to the CIS
minicolumn;
PG: prostaglandin family; LT: leukotriene
family; AA: arachidonic acid family.
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Comparison of the Effects of C2-ceramide, Sphingomyelinase,
and Dihydrocercunide on Arachidonic Acid Metabolism in Mouse
Peritoneal Macrophages (PEC)
To compare the effects of C2-ceramide,
sphingomyelinase, and dihydroceramide on arachidonic acid
metabolism in mouse PEC, mouse PEC were collected (1.1 x
10®/ml X 26 ml), washed, and labelled overnight as described
in "Materials and Methods". Following the same experimental
procedure as described above, C2-ceramide, sphingomyelinase,
and dihydroceramide were used to challenge the cells in RPMI
medium with 2.5% FBS at the concentrations of 2.5, 5, 10,
20, 40, 80 pM/ml, 0.03, 0.06, 0.125, 0.25, 0.5, 1 unit/ml,
and 2.5, 5, 10, 20, 40, 80 pM/ml, respectively. After four
hours incubation at 37°C in the chamber with 5% COg, all the
samples were collected, centrifuged, and transferred to
clean centrifuge tubes. A 100 pi aliquot from each sample
was removed and counted for total label released. As shown
in Fig. 21, both C2-ceramide and sphingomyelinase
activated arachidonic acid metabolism in mouse PEC.
Dihydroceramide had no apparent effect on this activation.
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Fig. 27: Comparison of the effects of C2-ceramide,
sphingomyelinase/ and dihydroceraimide on arachidonic acid
metabolism in mouse peritoneal macrophages (PEC).
Mouse PEC were collected (1.1 x 10® cells/ml x 24 ml),
washed, and labelled as described in the legend of Fig. 24.
The cells were then challenged with C2-ceramide or
dihydroceramide at 2.5, 5, 10, 20, 40, 80 pM/ml, or with
sphingomyelinase at 0.03, 0.06, 0.125, 0.25, 0.5, 1 unit/ml
in RPMI medium with 2.5% FBS for four hours. One ml samples
were then collected, centrifuged, and a 100 jil aliquot was
removed from each supernatant to count for total label
released from the cells.
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Effect of R595 LPS Pretreatment of Macrophage Cultures
(Mouse PEC) on Subsequent Challenge with S. minnesota LPS,
Cerconide, and Phorbol Myristic Acetate (PMA)
To understand the nature of desensitization by R595 LPS
treatment, mouse PEC were collected (2.54 x 10® cells/ml x
12 ml), washed, and treated with S. minnesota LPS at a
concentration of 100 ng/ml in RPMI medium with 10% FBS on a
24-well flat-bottom plate, 1 ml per well. Nine wells of the
cells were used as control (untreated) samples. After three
hours incubation at 37°C in the chamber with 5% CO2 , the
medium was removed, and RPMI medium containing ^Harachidonic acid was used to label the cells (0.5 |iCi/ml)
overnight as described before.
After overnight incubation, the medium was removed, and
the cells were washed three times with RPMI medium without
serum. Then S. minnesota LPS, ceramide, and PMA were used to
challenge both LPS treated and control (untreated) cells in
RPMI medium with 10% FBS at concentrations of 1000 ng/ml, 80
pM/ml, and 1000 ng/ml, respectively. Three wells of each
LPS-treated and untreated cells were used as control samples
for unchallenged cells. After two hours incubation at 37°c
in the chamber with 5% CO2 , one ml samples were removed,
centrifuged, and transferred to clean tubes. A 100 p.1
aliquot of the supernatant was removed from each sample and
counted for total label released. The remaining portion of
each sample was fractionated on CIS minicolumns.
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As shown in Fig. 28, for the untreated cells, 5. /
minnesota LPS activated arachidonic acid metabolism, and
ceramide was less effective for the activation. In contrast,
the pretreated cells showed no response to R595 LPS, but an
enhanced response to PMA. No apparent change of activation
was observed for the effect of ceramide between LPS-treated
and untreated mouse PEC. CIS minicolumn separation showed
that there was no apparent difference in the composition of
the eicosanoid mixture released from LPS-treated and
untreated mouse PEC which were challenged with S. minnesota
LPS and PMA. ^H-labelled polar products, arachidonic acid,
leukotrienes, and prostaglandins were all recovered from the
separation. Apparent difference was observed from the
separation of samples released from LPS-treated and
untreated mouse PEC which were challenged with ceramide. All
^H-labelled polar products, arachidonic acid, leukotrienes,
and prostaglandins were recovered from the samples released
from untreated cells. But only ^H-labelled polar products
and arachidonic acid were recovered from the samples
released from LPS-treated cells. No label was recovered in
the leukotriene and prostaglandin fractions (Fig. 29).
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Fig. 28: Effect of R595 LPS pretreatanent of macrophage
cultures (mouse PEC) on subsequent challenge with S.
minnesota LPS, C2-ceramide, and PMA.
Mouse PEC were collected (2.54 x 10® cells/ml x 6 ml),
washed, and pretreated with R595 LPS at a concentration of
100 ng/ml in RPMI medium with 10% FBS for three hours. The
medium was then removed, and the cells were labelled
overnight as described in the legend of Fig. 24. The cells
were then challenged with S. minnesota LPS at 1000 ng/ml,
C2-ceramide at 80 pM/ml, or PMA at 1000 ng/ml respectively
in RPMI medium with 10% FBS for two hours (hatched bar).
The same amount of untreated mouse PEC were labelled and
challenged following the same experimental procedure as
described above (solid bar). After two hours challenging,
all samples (1 ml each) were removed, centrifuged, and a 100
|il aliquot from each supernatant was taken to count for
total label released from the cells.
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Fig. 29: Eicosanoids released from activated mouse
peritoneal macrophages, both R595 LPS pretreated and
untreated, challenged with S. minnesota LPS, ceramide, or
PMA..
Mouse PEC were collected, pretreated with R595 LPS,labelled,
and challenged as described in the legend of Fig. 28. After
the 100 p.1 aliquot from each sample was taken to be counted,
the remaining portion of both R595 LPS pretreated and
untreated samples were fractionated on 018 minicolumns as
described in the legend of Fig. 9. Unbound: ^H-labelled
polar products which did not bind to the 018 minicolumn;
PG: prostaglandin family; LT: leukotriene family; AA;
arachidonic acid family.
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HPLC Analysis
Standard mixture containing unlabelled LTD4 (100 pmole)
plus ^H-PGEl (0,1 nCi), ^H-LTD4 (0.05 ^iCi) , and ^H-AA (0.15
p.Ci) was analysed through HPLC. The HPLC system was
performed as described in "Materials and Methods", and these
components were well quantified using the in line
radioactivity flow detector (Fig. 30) .
Samples released from THP-1 cells challenged with R595
LPS as described above were analysed with HPLC system, and
this analysis confirmed the Cl8 minicolumn separation result
that arachidonic acid was the main product in the eicosanoid
mixture released from the cells.(Fig. 31) .
Samples released from THP-1 cells challenged with R595
LPS as described above were fractionated on CIS minicolumns,
and the prostaglandin, leukotriene, and arachidonic acid
fractions were then concentrated and analysed with HPLC
system. Arachidonic acid was recovered as main product in
the arachidonic acid fraction. The HPLC system lacked the
sensitivity to detect label in the prostaglandin or
leukotriene fractions. When Samples were pooled,
concentrated, and then analysed with HPLC system, the
leukotriene fraction showed the peak which appeared in the
area where the peak of arachidonic acid appeared.
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Fig. 30: HPLC analysis of standard mixture of eicosanoids.
Standard mixture containing unlabeled LTD4 (100 pmole) plus
^H-PGEl (0.1 ixci) f ^H-LTD4 (0.05 nCi) , and ^H-AA (0.15 nCi)
was analysed through HPLC. HPLC was carried out on a 4.6 x
250 mm silica C18 column, which was attached to a PERKINELMER Series 410 LC pump and a FLO-ONE\Beta Series A-lOO
radioactivity detector. The solvent system was a low
pressure gradient of solvent A (acetonitrile:methanolzddHzO
:acetic acid:EDTA= 1280:800:1916:4:2 grams) and methanol
eluted at the flow rate of 1 ml/min in the following order:
0 min, 100% A; 30 min, 100% A; 31 min, 100% methanol; 51
min, 100% methanol; 52 min, 100% A; 67 min, 100% A.
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Fig. 31; HPLC analysis of eicosanoids released from human
THP-1 cells challenged with S.minnesota LPS.
Human THP-1 cells were pretreated/ labeled, and challenged
as described in the legend of Fig. 17. After counting 100
pi aliquot from each sample and running the EIA assay, all
the rest of samples were mixed together and analysed through
HPLC. HPLC system was performed as described in the legend
of Fig. 30.
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Membrane Phospholipid was not Recovered in Eicosanoid
Fractions Released from Activated Human THP-1 Cells
When lipid from the prostaglandin and leukotriene
fractions was concentrated and subsequently fractionated by
HPLC, all of the label eluted in the arachidonic acid
fraction. This suggested that these eicosanoid fractions
might have contained arachidonate esterified to more complex
lipid (e.g. phospholipid) and that the arachidonate was
hydrolyzed from the glycerol during concentration step.
In order to quantify the amount of arachidonate which
was released from cells as complex phospholipids, THP-1
cells were labeled with either ^H-arachidonic acid at 0.5
^iCi/ml or ^^P at 5 pCi/ml overnight. Both ^H-AA and ^^P
labeled cells were then challenged with either S. minnesota
LPS or S. faecalis LTA at 0, 0.1, 1, 10, 100, 1000 ng/ml in
RPMI medium with 5% FBS. After incubation at 37°C with 5%
CO2 for 2 hours, all samples were removed and then
centrifuged. A 200 |il aliquot of the supernatant was removed
from each sample and counted for total label released from
the cells, and the remaining portion of each sample was
fractionated on CIS minicolumns. As shown in Fig. 32, both
^H and ^^P was released from cells challenged with S.
minnesota LPS or S. faecalis LTA. CIS minicolumn separation
showed different results between ^H and ^^P labeled cells.
The recovery of ^H-label was similar to the results
described above, but almost all the ^^P- label was recovered
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in the water phase. The lipid which eluted from the C18
minicolumn in the prostaglandin or leukotriene fractions did
not appear to contain phospholipid (Fig. 33}.
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Fig. 32: Label released from human THP-1 cells challenged
at various concentrations with either S.minnesota (R595) LPS
or S.faecalls LTA.
Human THP-1 cells {8.6 x 10^ cells/ml x 15 ml) were
pretreated with vitamin D3 (1 pM/ml) and metabolically
labeled with either ^H-arachidonic acid at 0.5 pCi/ml or
at 5 pCi/ml overnight. The cells were then challenged with
either S.minnesota LPS or S.faecalis LTA at the
concentration course of 0, 0.1, 1, 10, 100, 1000 ng/ml in
RPMI medium with 5% FBS for two hours. One ml samples were
then collected, centrifuged, and a 200 |il aliquot of each
supernatant was counted to determine total label released
from the cells.
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Fig. 33: Eicosanoids released from activated human THP-1
cells challenged with S.minnesota LPS or S.faecalis LTA.
Human THP-1 cells were pretreated# labeled, and challenged
as described in the legend of Fig. 32. After the 200 nl
aliquot was removed from each sample to be counted, the
remaining portion of each smaple was fractionated on C18
minicolumns as described in the legend of Fig. 9. Unbound:
^H-labeled polar products which did not bind to the C18
minicolumn;
PG: prostaglandin family; LT: leukotriene
family; AA: arachidonic acid family.
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Chapter IV
DISCUSSION

Development for Rapid Separation of Different Eicosanoids
Many techniques have been used to separate and extract
different eicosanoids. Classical techniques for extraction
of prostaglandins or leukotrienes from biological fluids and
plasma are liquid - liquid or liquid- solid extractions. In
liquid - liquid extractions, many different organic
solvents, such as chloroform, diethyl ether or ethyl acetate
have been used (27) . However, this technique is timeconsuming because multi-step extractions and large volumes
of organic solvents may be necessary for an efficient
extraction. Liquid - solid extractions have employed solid
adsorbents such as silica or octadecylsilane silica
materials from which adsorption of a compound from the
liquid phase onto the adsorbent material and subsequent
desorption may result in different recoveries depending on
the type of adsorbent utilized. Silica and CIS (CDS)
extraction columns (Sep-Paks) are the most common choice.
Another octadecylsilane silica material available in
disposable columns of different sizes distributed by J.T
Baker has also been found to accomplish the extraction of
prostaglandins and lipoxygenase metabolites of arachidonic
acid from buffer with good recoveries (27).
Based on previous research results from our laboratory
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(4), the major classes of eicosanoids we were interested in
were the prostaglandin family, leukotriene family, and
arachidonic acid. Several groups have described procedures
to extract prostaglandins or leukotrienes from plasma or
other biological fluids, however, a technique for
simultaneous extraction and separation of all
prostaglandins, leukotrienes, and arachidonic acid has not
been demonstrated. A major objective of this present study
was to develop a procedure for the simultaneous extraction
and separation of the three classes of eicosanoids with
liquid - solid extraction technique based on the solid
adsorbents and using organic solvents which have been
used in HPLC or TLC procedures.

Comparison of Eicosanoid Separation Efficiency of Silicic
Acid Column Procedure and C18 Minicolumn Procedure
Initial studies for quick separation of different
eicosanoids were focused on the evaluation of one-step
column-centrifugation procedures. For our initial
experiments, small centrifuge columns were developed using
silicic acid as absorbant, which was expected to have
markedly different affinities for the prostaglandin family
and the leukotriene family. It was essential that all of the
different eicosanoids have high binding affinity in the
initial solvent. Each of the eicosanoids could then be
sequentially eluted with different solvents. We tested
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the binding affinity of the eicosanoids in different
solvents/ and toluene was finally selected as the solvent
for loading samples on silicic acid columns. For both the
silicic acid procedure and CIS minicolumn procedure, the
solvent systems evaluated in this study for sequential
elution were selected from solvents which have been used in
thin-layer chromatography (TLC) and HPLC systems.
Fractionation of the different classes of eicosanoids on
hydrophobic CIS minicolumns or silicic acid columns is based
on the difference in polarity of leukotrienes (LT),prostaglandins (PG) , and arachidonic acid (AA.) (polarity :
PG > LT > A A ) . The silicic acid column procedure required
more complicated solvent systems than the CIS minicolumn
procedure, and this procedure was only effective for
separation of leukotrienes from prostaglandins and
arachidonic acid, but not for separation of prostaglandins
and arachidonic acid (Fig. 11) .
Neither the separation or the recovery of this procedure was
as effective as the CIS minicolumn procedure (Fig. 10, 13) .
Based on these observations, the CIS minicolumn procedure
was finally selected for eicosanoid analysis in this study.

LPS and LTA Activate Eicosanoid Metabolism in Human THP-1
Cell Line
The human monocytic leukemic cell line, THP-1, which
differentiates toward macrophages in response to phorbol

1 2

myristate 13-acetate (PMA) or vitamin D3, is an established
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model of induced macrophage differentiation (3). After
differentiation with 1,25-dihydroxyvitamin D3^ previous
studies showed that THP-1 cells responded to LPS stimulation
with a greatly enhanced secretion of proinflammatory
cytokines and mediators including TNF-a and the arachidonic
acid metabolites, such as prostaglandin E2 (PGE2),
thromboxane B2, and prostaglandin F2a (PGF2a). This
increase required the expression of the CD14 antigen, an
integral component of a high-affinity LPS receptor (20). Our
results indicated that THP-1 cells responded well to
activation with LPS from S. minnesota (R595) and S. abortus,
and to lipoteichoic acid from S. faecalis, S.pyogenes,
B.subtilis, and S.aureus. Activation significantly enhanced
release, which was concentration-dependent and time
dependent, of arachidonic acid metabolites.
The rate-limiting enzyme in the arachidonic acid
cascade is phospholipase A 2 (PLA2 ), which cleaves
arachidonic acid residues from membrane phospholipids. This
enzyme was reported to be activated by LPS in macrophages,
causing it to localize to the plasma membrane and release
arachidonic acid (20). It has been documented that relative
potency of LPS varied with the proportion of lipid A in the
LPS molecule. Previous studies indicated that the ratio of
lipid A to polysaccharide in LPS has significant influence
on the cellular mechanisms and subsequent toxic effects of
endotoxins and the consequence of gram-negative bacterial
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infections. Due to the structural differences between
S. minnesota LPS (R-LPS) and S. abortus LPS (S-LPS), they
might have different effects on the activation of
phospholipase A 2 , causing different subsequent
pathophysiological consequences.
Our results of CIS minicolumn separation showed there
were some differences of the arachidonic acid metabolites
released from THP-1 cells challenged with either S.
minnesota or S. abortus LPS. Both arachidonic acid and
leukotrienes, which are the 5'-lipoxygenase products, were
recovered from the mixture of eicosanoids released from THP1 cells which were challenged with S. minnesota LPS, but no
measurable amount of prostaglandins were found. In contrast,
only arachidonic acid was recovered from the eicosanoid
mixture released from THP-1 cells challenged with smooth-LPS
from S. abortus, suggesting that S. abortus LPS stimulation
did not activate the 5'-lipoxygenase pathway in the THP-1
cell line. Label was recovered, however, in the leukotriene
fraction from THP-1 cells challenged with S. minnesota
(R595) LPS, indicating that the 5'-lipoxygenase pathway
was activated in these cells.
Chemically, LTA is different from LPS, but it shares
some common physical properties with LPS. LTA is localized
at the outer surface of the cytoplasmic membrane of Grampositive bacteria (11). Both LTA and LPS are anionic,
amphiphilic polymers, which contain carbohydrate and
phosphorus, and both have a hydrophobic glycolipid moiety
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and a hydrophilic end. LTA induces some of the same
biological and immunological responses which are induced by
LPS, but compared with LPS, LTA is less toxic. There are
differences in the relative potencies of different LTA
preparations. In mouse PEC cultures, S. faecalis and S.
aureus LTA are comparable to LPS, whereas B. subtilis LTA
is less potent (4). In this study, we used LTA from S.
faecalisr S.pyogenes^ B.subtilis^ and S.aureus to challenge
both THP-1 cells and mouse PEC macrophages. Our results
indicated that THP-1 cells responded well to the stimulation
from all of these LTA preparations. C18 minicolumn
separation of the eicosanoid mixture showed compositions
similar to that released by S. minnesota LPS (R595)
challenged cells. Both arachidonic acid and leukotrienes
were recovered from the separation, but no measurable
prostaglandins were found. These results suggested
that the pathway of cell activation by these LTA
preparations was similar to the activation pathway of R595
LPS. They could activate both phospholipase A 2 and 5'lipoxygenase pathways, causing the release of arachidonic
acid and leukotrienes. No label was recovered in the
prostaglandin fraction. The key enzymes in prostaglandin
synthesis are the constitutive cyclooxygenase, prostaglandin
H synthase-1

(PGHS-l), and the mitogen-induced

cyclooxygenase (PGHS-2). The C18 minicolumn separation
results suggest that cyclooxygenase pathway is not activated
in the human THP-1 cell line. The result that LTA had
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similar effect as LPS on stimulating arachidonic acid
release in human THP-1 cells is quite interesting since LTA
is less toxic than LPS, and it has not been implicated in
pathological conditions.
HPLC system was applied in this study to analyse each
fraction of prostaglandin, leukotriene, or arachidonic acid,
which were fractionated on CIS minicolumns. HPLC analysis
confirmed the CIS minicolumn separation results that
arachidonic acid was the main product in eicosanoid mixture
released from THP-1 cells challenged with S. minnesota LPS.
The HPLC analysis lacked the sensitivity to detect label in
the prostaglandin and leukotriene fractions. In order to
increase sensitivity, the leukotriene fractions from several
samples were pooled, concentrated by evaporation, and then
analysed by HPLC. All of the label in these pooled samples
was eluted in the arachidonic acid fraction. Since the
amount of arachidonic acid in the eicosanoid mixture was
much higher than the amount of prostaglandins or
leukotrienes, it was possible that when the mixture was
fractionated on CIS minicolumn, some arachidonic acid
might be eluted with the leukotriene fraction, causing the
recovery of arachidonic acid in leukotriene fraction with
HPLC analysis. This is unlikely, however, because when the
label recovered in the leukotriene fraction was applied to a
fresh column and re-fractionated all of the label was again
recovered in the leukotriene fraction. The same results were
obtained when label recovered in the prostaglandin fraction
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was refractionated. Another possible explanation for this
observation could be that some other products, which were
eluted in the PG or LT fraction on the column but
subsequently chromatographied with AA on the HPLC, were
released from the THP-1 cells during the R595 LPS
challenge. Since we just used ^H-LTD4, ^H-PGEl, and ^H-AA as
standards for HPLC analysis and also for C18 minicolumn
procedure, it is very possible that some other products
which could be separated from arachidonic acid on the column
but not on HPLC.
In contrast, EIA assay results showed that both PGE2
and LTC4 were recovered from the eicosanoid mixture released
from THP-1 cells challenged with S. minnesota LPS. But
compared with LTC4, the amount of PGE2 was much less. The
amount of PG measured by EIA was below the sensitivity of
the HPLC. EIA assay could measure prostaglandins at the
concentration as low as 5 pg/ml. A very low amount of PGE2
in eicosanoid mixture could not be detected with C18
minicolumn procedure or HPLC assay, but it could be measured
with EIA assay.

S. minnesota LPS, S. faecalis LTA and PMA Activate
Eicosanoid Metabolism in Mouse Peritoneal Macrophages
The toxicity of lipopolysaccharide is a problem in the
practical use of LPS to enhance the immune response. This
has led to a search for naturally occurring or modified
forms of LPS which have reduced toxicity but retain immune
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stimulatory activity. Much evidence has suggested that the
endotoxic properties of LPS are largely determined by the
lipid A component which interacts with a defined humoral
factor (LPS binding protein) and the cellular recognition
molecular receptor, CD14. The toxicity levels of different
lipid A preparations show marked differences (5). Removal of
a phosphate group from lipid A results in a marked reduction
in pyrogenicity and toxicity. Likewise, removal or
substitution of the normal fatty acids of lipid A causes
decreased toxicity (4). Although lipid A is considered to be
responsible for virtually all the biological activities of
LPS, the polysaccharide moiety determines the elimination
kinetics, LPS binding specificity with macrophages, and the
activation of the alternate pathway of the complement
system. This is at least part of the reason that smooth and
rough LPS have differential effects on the release of
chemical mediators.
It has been previously demonstrated that smooth LPS
from Pasteurella hemolytica caused marked increases in
plasma PG, TxB2 and serotonin in sheep (7). Emau and Giri
reported (8 ) that both smooth and rough LPS caused immediate
increases in plasma arachidonic acid to its maximal levels
at various times during the infusion, and the rise in plasma
arachidonic acid metabolites was greater in response to
smooth than to rough LPS. They also found although both
smooth and rough LPS produced an early transient rise in
plasma serotonin, the two LPSs differed in their abilities
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to decrease plasma serotonin and histamine during the later
part of endotoxemia.
LTA was also reported to stimulate the respiratory
burst in human blood monocytes (17), but the immunological
implications of the interaction of LTA with cells for the
immune response remains unclear. Some previous results
suggested that LTA would interact with host immune cells
directly. The hydrophobic component of LTA is less complex
than lipid A of LPS, and it has been proposed that the
reason LTA is less toxic is because LTA is closer in
structure to eukaryotic membrane glycolipids than lipid
A (34) . It has been suggested that the hydrophobic
glycolipid region would be the biologically active part in
LTA for attachment to unidentified receptor(s) on the
surface of macrophages, such as lipid A in LPS is the
minimal structure which is responsible for most of the
biological properties .of LPS (18).
In our laboratory, Rahul Jasuja reported (4) that
lipoteichoic acid (LTA) from the Gram-positive bacteria S.
aureus, S. faecalis, B. subtilis, and B. stearothermophilus
activated eicosanoid release from mouse peritoneal
macrophages (mouse PEC). The amount of arachidonic acid
released was comparable to that released by mouse PEC which
were activated with toxic LPS from S. abortus. B. subtilis
LTA stimulated arachidonic acid release, but the amount
released was much less than the other LTA preparations.
Lipopolysaccharide (LPS) from S. abortus initiated
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eicosanoid release and showed a maximum release at lower
concentrations than LTA. The total amount of eicosanoids
released was about the same for LPS and S. aureus and
S. faecalis LTA. Phorbol myristic acetate (PMA) was also
tested, and the result showed it was another activator for
arachidonic acid metabolism. It has been known that PMA,
which is an analog of diacylglycerol, can permeate the cell
membrane and activate protein kinase C, causing the release
of arachidonic acid via phospholipase Az (35). This previous
study did not determine the relative amount of the different
classes of eicosanoids in the materials released from
different cell lines.
My study confirmed that S. minnesota LPS (smooth LPS),
S. faecalis LTA, and PMA activated eicosanoid metabolism in
mouse peritoneal macrophages (mouse PEC). Furthermore, CIS
minicolumn separation showed that prostaglandins,
leukotrienes, and arachidonic acid were recovered in the
eicosanoid mixture released from mouse PEC challenged with
R595 LPS, LTA, and PMA, indicating that both cyclooxygenase
and 5'-lipoxygenase pathways were activated in mouse PEC.

Comparison of the Effect of S. minnesota LPS, S. faecalis
LTA, and PMA on Eicosanoid Metabolism in Human THP-1 cells
and Mouse Peritoneal Macrophages
There were marked differences in the relative amount of
different eicosanoids recovered from the mixture released
from mouse PEC or human THP-1 cells. When both of the cell
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lines were challenged with S. minnesota LPS, S. faecalis
LTA, and PMA, CIS minicolumn separation of eicosanoid
mixtures from activated mouse PEC showed label in the
prostaglandin, leukotriene, and arachidonic acid fractions.
Only the leukotriene and arachidonic acid fractions were
recovered from human THP-1 cells. This result is quite
interesting since the same results were obtained by
stimulation with LPS, LTA, or even PMA, which is not a
bacterial amphiphile. The type of eicosanoids released did
not vary with the type of activation but with the different
cell lines. The constitutive cyclooxygenase PGHS-1 and
inducible cyclooxygenase PGHS-2 are responsible for
prostaglandin synthesis, whereas 5'-lipoxygenase is
responsible for leukotriene synthesis. It has been reported
that the mitogen-inducible cyclooxygenase, PGHS-2, could be
induced upon LPS stimulation in THP-1 monocytes, and is
generally thought to be the isoform responsible for the
resultant burst of prostaglandin and thromboxane synthesis
(24). Recently, Mazzucco and Warr reported (20) that the
fungal metabolite trichodimerol (BMS-182123), which
has demonstrated inhibition of LPS-stimulated tumor necrosis
factor-a (TNF-a) secretion in both human and murine in
vitro macrophage models, interfered with LPS-induced
eicosanoid secretion through an inhibition in the induction
of the inducible cyclooxygenase, PGHS-2, at the level of
transcription.
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In this study/ little prostaglandin was released from
THP-1 cells challenged with LPS, LTA, and PMA. On the other
hand, the stimulation of the amphiphiles (both LPS and LTA)
and PMA could activate the cyclooxygenase pathway in mouse
peritoneal macrophages, resulting in the release of
prostaglandins. The mechanisms for this preferable
activation need further studies.
Another comparison of the effect of LPS, LTA, and PMA
on eicosanoid metabolism in human THP-1 cells and mouse PEC
shows that LPS, LTA and PMA activate these two cell lines
with different stimulative potency. Both of the cell lines
could responded well to LPS (R595), LTA (S. faecalis) , and
PMA stimulation and released eicosanoids. But R595 LPS
appeared to have

the most potent

stimulativeeffect on THP-1

cells, releasing

two times more eicosanoid than PMA. On the

other hand, PMA was the most potent activator for eicosanoid
metabolism in mouse PEC, and S. faecalis LTA had the least
effect for this activation.
PMA acts as an analogue for diglyceride. A possible
explanation for this
binding affinity

observation

for the protein

is that PMAhas different ,
kinase C inthese two cell

lines. DAG is a source for arachidonic acid by the action of
diglyceride lipase, and it also can activate protein kinase
C, which plays an important role in leukocyte activation,
differentiation of monocytes to macrophages, and arachidonic
acid release (Fig. 34). It has been previously reported that
PMA could specially activate protein kinase C, causing the
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release of arachidonic acid. Based on our observation, we
suggest that PMA might have lower binding ability in THP-1
cells compared with in mouse PEC, resulting in lower protein
kinase C activation. Another possibility is that in THP-1
cells, protein kinase C may not be linked with the
arachidonic acid metabolic pathway as closely as in mouse
PEC, so that this enzyme has less of an effect on
arachidonic acid release in THP-1 cells.
The reason that LPS and LTA have different effects on
eicosanoid release in THP-1 and mouse cells might be related
to their different receptors on the cells. Several LPS
receptors have been identified. The 53- to 55-kDa cell
surface glycoprotein CD14, which is a
glycophosphatidylinositol anchored protein, has been
identified as the main LPS receptor on leukocytes, enabling
them to be stimulated with LPS by binding serum LPS-binding
protein (LBP)-LPS complexes at low LPS concentrations. This
process is facilitated by the catalytic activity of the
serum protein LPS-binding protein (LBP), which accelerates
the binding of LPS to CD14 (32). CD18 and LDL-scavenger
receptor are also LPS receptors, but they do not appear to
be involved in signal transduction. Receptors of LTA
have not been identified. LTA has not been found to bind
the CD14 receptor, but it has been pointed out that LTA from
several Gram-positive bacteria binds a 28 kDa LPS binding
protein in mouse serum (19). Previous investigations showed
that the macrophage scavenger receptor (SR), a glycosylated
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trimeric transmembrane protein, binds directly to many Grampositive bacteria, possibly via LTA. SR binding to other
ligands is dependent upon the spatial characteristics of the
repeating negative charge of the ligand. Therefore,
Greenberg and Fischer (12) investigated SR recognition of
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R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

84

LTA species with various charge densities and distributions,
and they demonstrated that the SR binds directly to many
Gram-positive bacteria via negative charges and possibly
also recognizes polyanionic hydrophilic chains of LTAs.
Their data support the role of surface associated LTA as a
major ligand of Gram-positive bacteria for binding to SR.
Based on our findings, we suggest that the distribution of
LPS and LTA receptors on these two cell lines is different.
Both LPS and LTA receptors which could function in signal
transductions might be more abundant on THP-1 cells than
on mouse PEC. This different distribution of the receptors
could lead to the different stimulative potency of LPS and
LTA on these two cell lines, causing more eicosanoids
released from THP-1 cells than from mouse PEC when
challenged with LPS or LTA. The other possibility that could
explain our results would be that the LPS and LTA receptor
on mouse cells might not be linked to the arachidonic acid
metabolic pathway as closely as in THP-1 cells, so LPS or
LTA challenging has less effect on activating arachidonic
acid metabolism in mouse cells than human THP-1 cells.

The Nature of Desensitization by S. minnesota (R595) LPS
Treatment in Mouse Peritoneal Macrophages
We tested the ability of S. minnesota LPS to
desensitize mouse peritoneal macrophages, and the data
presented in our study showed the treatment with R595 LPS
desensitized the macrophage cultures to subsequent response
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to LPS challenge. Furthermore, we found that the cell
culture pretreated with R595 LPS had good response to PMA
challenge, releasing even more eicosanoids than the cells
without LPS pretreatment.
Rahul Jasuja reported (4) that S. faecalis and S.
aureus LTA desensitized mouse PEC to LPS challenge, but B.
subtilis LTA could not. He also found that the
desensitization was not specific for pretreatment with LTA.
Mouse PEC pretreated with LPS were desensitized to LPS
challenge, and cells pretreated with LTA were unresponsive
to subsequent LTA challenge. But S. faecalis LTA could not
desensitize the cells to PMA and calcium ionophore A231B7
challenge. My study confirmed that R595 LPS could
desensitize mouse PEC to LPS challenge, and the CIS
minicolumn separation result showed the main classes of
eicosanoids released from either desensitized or non
desensitized cells were similar.
Previous studies from our laboratory (4) indicated that
the desensitization was not the result of less [^H]arachidonic acid uptake during the labeling period, or the
result of a general down-régulâtion of arachidonic acid
metabolism. Cells pretreated with LTA during the adherence
period had an enhanced rate of uptake of [^H]-arachidonate
during the labeling period, and remained responsive to PMA
challenge, indicating that there was an increase in the
turnover of arachidonic acid in these stimulated cells,
resulting in an increase in both uptake and release. There

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

86

are several possible mechanisms which may be responsible for
the desensitization of cells to LPS challenge, such as
alterations of amphiphile receptors, the targets of
signal transduction, or the cellular regulators of the
signal transduction pathways. The best characterized LPS
receptor CD14, as described above, can function by
delivering LPS to the signaling receptor. GDI 8 and the LDLscavenger receptor have not been reported to function in
signal transduction. Previous results suggested that
blocking these receptors does not desensitize cells to LPS
challenge, and the desensitization is not the result of a
down-regulation of any of the known receptors (9). The
possible explanations for desensitization could be
that it is the result of changes in cellular elements
involved in the interaction of the receptor and transduction
system or some single step in signal transduction pathways.
Both tyrosine kinase and protein kinase C have been
implicated in the LPS activation pathway. As shown in Fig.
34, in the pathway of arachidonic acid release, the steps
for cells desensitized with LPS could occur at a point
before protein kinase C activation.
We also found that R595 LPS pretreatment could not
desensitize mouse PEC to PMA challenge, which was similar to
Jasuja's (4) observation that S .faecalis LTA could not
desensitize mouse PEC to PMA challenge. It has been shown
that the mechanism for PMA activating arachidonic acid
metabolism is that PMA permeates the cell membrane and
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directly activates protein kinase C, causing arachidonic
acid release via phospholipase A 2 . This mechanism could
explain the result that R595 LPS and S. faecalis LTA
pretreatment did not desensitize cells to PMA challenge
since the pretreatment caused desensitization step which
occurred at a point before protein kinase C activation, so
the subsequent treatment of PMA still activated protein
kinase C, causing the release of arachidonic acid. Our
observation that subsequent PMA challenge of R595 LPS
pretreated cells caused even more arachidonic acid release
than untreated cells could be due to the three hours
pretreatment of R595 LPS. Previous study in our laboratory
(4) indicated that mouse PEC pretreated with LTA from S.
pyogenesf S.aureus, and S. faecalis during the adherence
period had an enhanced rate of uptake of [^H]-arachidonate
during the labeling period. Based on this observation, the
explanation for our result is that pretreatment with R595
LPS enhanced the uptake of [^H] arachidonate during the
labeling period, which would increase the amount of label in
the lipid pool, so that more arachidonic acid was released
during subsequent PMA challenge.
It has been suggested that ceramide is an intracellular
modulator of cell growth and differentiation, and it is also
an important second messenger in signal transduction in
cells of myeloid lineage (15). Examination of the structures
of LPS and ceramide have revealed a strong similarity
between the molecules. This present study showed that C2-
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ceramide and sphingomyelinase had the effect on activating
arachidonic acid metabolism in mouse PEC, and
dihydroceramide, which was used as a negative control, had
no apparent effect on this activation. R595 LPS could not
desensitize the cells to subsequent challenge with C2ceramide or PMA. Most recently, Jean Pfau (unpublished data)
in our laboratory reported that both LPS and ceramide could
activate arachidonic acid metabolism in human THP-1 cells,
and prior exposure to ceramide did not desensitize the cells
to subsequent challenge with either LPS or ceramide, nor
could LPS desensitize the cells to challenge with ceramide,
which is very similar to our result in mouse PEC.
Macrophage-endotoxin interaction has many destructive
pathophysiological consequences, such as endotoxic shock.
Desensitization of the responding cells by pretreatment with
bacterial amphiphiles could be an effective method for
minimizing the harmful effects caused by macrophageendotoxin interaction.
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Summary

1.

A CIS minicolumn procedure was developed to separate
different eicosanoid mixtures into prostaglandin
fraction, leukotriene fraction, and arachidonic acid
fraction.

2.

The relative amount of label in the different
eicosanoid fractions released from LPS activated THP-1
cells was similar throughout the activation period.
THP-1 macrophages activated with LPS from S. minnesota
(R595) released both PGEz and LTC4 .

3.

The kinetics of activation of THP-1 cells with
lipoteichoic acid were similar to the kinetics of cells
activated with LPS. The relative amount of label
recovered in different eicosanoid fractions was similar
for THP-1 cells activated with different LTA
preparations.

4.

Pretreatment of THP-1 cells with human gamma interferon
did not alter the pattern of arachidonic acid
metabolism.

5-

Mouse peritoneal macrophages (PEC) were more sensitive
to PMA than human THP-1 macrophages.
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6

.

R595 LPS pretreatment desensitized mouse peritoneal
macrophages to subsequent challenge with R595 LPS, but
this treatment could not desensitize the macrophage
cultures to subsequent challenge with either C2ceramide or PMA.

7.

The composition of the eicosanoid mixture released from
PMA treated THP-1 cells was similar to LPS and LTA
treated cells.

8

.

Mouse PEC cultures released more label in the
prostaglandin fraction than human THP-1 cells.

9.

HPLC analysis comfirmed the CIS minicolumn separation
results that arachidonic acid was the main product
released from THP-1 cells challenged with S. minnesota
LPS, and no measurable amount of prostaglandin was
recovered. HPLC

result also suggested that some

product other than prostaglandins or leukotrienes was
released from THP-1 cells during this challenging.
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